BiotechTube
OncoLux

OncoLux

Houston, United States· Est.
oncoluxinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

OncoLux is pioneering a 'See and Treat' platform for intraoperative cancer care, merging advanced photonics and AI to visualize and immediately treat residual disease. Its LUMIS™ platform is designed for use in minimally invasive and robotic surgeries, with a Phase II trial ongoing in colorectal cancer and a planned First-in-Human study in lung cancer for 2027. The company aims to reduce cancer recurrence by ensuring more complete tumor removal during the initial surgical intervention.

OncologyColorectal CancerLung Cancer

Technology Platform

LUMIS™ platform: An integrated optical theranostics system combining multispectral fluorescence imaging for real-time cancer visualization with in-situ photodynamic therapy (PDT) for immediate treatment of residual disease. Utilizes advanced photonics and AI for data analysis and is designed for minimally invasive and robotic surgeries.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The platform addresses a major unmet need in surgical oncology by aiming to reduce local recurrence, which could command a premium price based on improved patient outcomes and reduced downstream costs.
The integration with robotic surgery aligns with a major growth trend in surgical care, facilitating adoption.

Risk Factors

Clinical failure in ongoing Phase II trials is an existential risk.
Regulatory pathway for a combined imaging/therapy device is complex.
Commercialization faces challenges in changing established surgical workflows and competing with larger companies in adjacent imaging spaces.

Competitive Landscape

Competes in the broader intraoperative imaging market (e.g., fluorescence imaging systems from Stryker, Olympus, Karl Storz) and the emerging field of targeted intraoperative therapies. Its integrated 'See and Treat' theranostics approach is distinctive but may face competition from companies developing standalone margin assessment tools or alternative ablation technologies.

More companies in Diagnostics & Precision Medicine →More companies in United States →